论文部分内容阅读
目的探究不同剂量丙种球蛋白治疗小儿黏膜皮肤淋巴结综合征的临床疗效。方法选取该院2012年5月-2014年6月儿科住院治疗的黏膜皮肤淋巴结综合征患儿84例,分为治疗组(42例)和对照组(42例),其中治疗组单次给予大剂量丙种球蛋白进行治疗;对照组分多次给予小剂量丙种球蛋白进行治疗。观察探究两组患儿的治疗效果。结果两组患儿治疗5 d后均取得了满意的临床效果,其中治疗组有效率为100.00%,对照组有效率为93.75%,两组对比,差异有统计学意义(P<0.05)。治疗组患儿心肌病变发生率为21.86%,对照组为37.80%,两组对比,差异有统计学意义(P<0.05)。治疗组患儿冠状动脉病变发生率为18.75%,对照组为46.86%,两组对比,差异有统计学意义(P<0.05)。结论大剂量丙种球蛋白治疗小儿黏膜皮肤淋巴结综合征的临床疗效明显优于较小剂量组,且患儿发生心肌病变及冠状动脉病变的几率小,值得临床推广。
Objective To investigate the clinical efficacy of different doses of gamma globulin in the treatment of children with mucosal cutaneous lymph node syndrome. Methods Eighty-four children with mucosal cutaneous lymph node syndrome admitted to our hospital from May 2012 to June 2014 were divided into treatment group (n = 42) and control group (n = 42). The treatment group was treated with large Dose of gamma globulin for treatment; control component was given multiple doses of gamma globulin for treatment. Observe the therapeutic effect of two groups of children. Results Both groups achieved satisfactory clinical results after 5 days of treatment. The effective rate was 100.00% in the treatment group and 93.75% in the control group. The difference between the two groups was statistically significant (P <0.05). The incidence of cardiomyopathy in treatment group was 21.86%, while that in control group was 37.80%. There was significant difference between the two groups (P <0.05). The incidence of coronary artery lesions was 18.75% in the treatment group and 46.86% in the control group. There was significant difference between the two groups (P <0.05). Conclusion The clinical efficacy of high-dose gamma globulin in treating children with mucosal cutaneous lymph node syndrome is significantly better than that of the lower dose group. The incidence of cardiomyopathy and coronary artery disease in children is small, which is worthy of clinical promotion.